Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy

Sarva Jayaprakash, Xinning Wang, Warren D. Heston, Alan P. Kozikowski

Research output: Contribution to journalArticlepeer-review

Abstract

Prostate-specific membrane antigen (PSMA) provides an attractive target for the development of targeted chemotherapeutics for prostate cancer. We have designed and synthesized a bioconjugate 1 that comprises the cytotoxic drug doxorubicin and one of our previously described urea-based PSMA inhibitors. While this bioconjugate retained high binding affinity for PSMA, it inhibited only 30% of C4-2 cell growth at a concentration of 5.0 μM.

Original languageEnglish (US)
Pages (from-to)299-302
Number of pages4
JournalChemMedChem
Volume1
Issue number3
DOIs
StatePublished - Mar 1 2006

Keywords

  • Doxorubicin
  • Inhibitors
  • Neurotransmitters
  • PSMA
  • Prostate cancer

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry

Fingerprint Dive into the research topics of 'Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy'. Together they form a unique fingerprint.

Cite this